TCHP and neoplasm: In recent years, some studies (Demmers et al., 2020) have correlated organoid proteomics with HLA peptide ligandomics, it was found that tumor-specific ligands derived from DNA damage and tumor suppressor proteins were significantly present in tumor cells, and there was heterogeneity in HLA peptide expression among individual patients, which led to the speculation that potential peptide tumor vaccines might be a feasible way to reduce the risk of immune escape.